Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
P Sun, L Meng - Acta Pharmacologica Sinica, 2020 - nature.com
Immune system-mediated tumor killing has revolutionized anti-tumor therapies, providing
long-term and durable responses in some patients. The phosphoinositide 3-kinase (PI3K) …
long-term and durable responses in some patients. The phosphoinositide 3-kinase (PI3K) …
Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy
PGS Makker, SS Duffy, JG Lees, CJ Perera, RS Tonkin… - PloS one, 2017 - journals.plos.org
Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain is a
debilitating adverse effect of cancer treatment. Current understanding of the mechanisms …
debilitating adverse effect of cancer treatment. Current understanding of the mechanisms …
Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image …
Background The clinical efficacy observed with inhibitors of programed cell death
1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to …
1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to …
Oncogenic β-catenin stimulation of AKT2–CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer
F Liu, X Gai, Y Wu, B Zhang, X Wu… - Proceedings of the …, 2022 - National Acad Sciences
CTNNB1, encoding β-catenin protein, is the most frequently altered proto-oncogene in
hepatic neoplasms. In this study, we studied the significance and pathological mechanism of …
hepatic neoplasms. In this study, we studied the significance and pathological mechanism of …
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
S Rahimian, MF Fransen, JW Kleinovink, M Amidi… - Biomaterials, 2015 - Elsevier
This study investigated the feasibility of the use of polymeric microparticles for sustained and
local delivery of immunomodulatory antibodies in immunotherapy of cancer. Local delivery …
local delivery of immunomodulatory antibodies in immunotherapy of cancer. Local delivery …
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin is highly
expressed in many tumor types and has reported prognostic value. To generate tumor …
expressed in many tumor types and has reported prognostic value. To generate tumor …
Emerging ways to treat breast cancer: will promises be met?
Background Breast cancer (BC) is the most common cancer among women and it is
responsible for more than 40,000 deaths in the United States and more than 500,000 deaths …
responsible for more than 40,000 deaths in the United States and more than 500,000 deaths …
[HTML][HTML] Excellent response to chemotherapy post immunotherapy
Methods We have a cohort of six patients who had disease progression on second line
Immunotherapy for solid or hematological malignancies and had ECOG< 2. All these …
Immunotherapy for solid or hematological malignancies and had ECOG< 2. All these …
Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures
L Li, J Zhou, X Dong, Q Liao, D Zhou, Y Zhou - International …, 2022 - Elsevier
Glioblastoma (GBM) is a heterogeneous and invasive WHO grade IV brain tumor. Patients
with GBM have a median overall survival (OS) of only 14 to 17 months when treated with …
with GBM have a median overall survival (OS) of only 14 to 17 months when treated with …